[1] CHEN L, RUAN G C, CHENG Y, et al.The role of Th17 cells in inflammatory bowel disease and the research progress[J].Frontiers in Immunology, 2022, 13:1055914.
[2] OKAMOTO R, WATANABE M.Role of epithelial cells in the pathogenesis and treatment of inflammatory bowel disease[J].Journal of Gastroenterology, 2016, 51(1):11-21.
[3] OKUMURA R, TAKEDA K.Maintenance of intestinal homeostasis by mucosal barriers[J].Inflammation and Regeneration, 2018, 38:5.
[4] 鞠林. 益生菌作用机制研究进展[J].山东畜牧兽医, 2023, 44(4):79-80;84.
JU L.Research progress on the mechanism of probiotics[J].Shandong Journal of Animal Science and Veterinary Medicine, 2023, 44(4):79-80;84.
[5] 王梦楠, 秦合伟, 郭宁, 等.下一代益生菌防治动脉粥样硬化的研究进展[J].中国比较医学杂志, 2022, 32(12):95-102.
WANG M N, QIN H W, GUO N, et al.Research progress in the prevention and treatment of atherosclerosis using next-generation probiotics[J].Chinese Journal of Comparative Medicine, 2022, 32(12):95-102.
[6] DUNCAN S H, HOLD G L, HARMSEN H J M, et al.Growth requirements and fermentation products of Fusobacterium prausnitzii, and a proposal to reclassify it as Faecalibacterium prausnitzii gen.nov., comb.nov[J].International Journal of Systematic and Evolutionary Microbiology, 2002, 52(Pt 6):2141-2146.
[7] AL-BAYATI L, NAYERI FASAEI B, MERAT S, et al.Quantitative analysis of the three gut microbiota in UC and non-UC patients using real-time PCR[J].Microbial Pathogenesis, 2023, 181:106198.
[8] SOKOL H, PIGNEUR B, WATTERLOT L, et al.Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients[J].Proceedings of the National Academy of Sciences of the United States of America, 2008, 105(43):16731-16736.
[9] KAWADE Y, SAKAI M, OKAMORI M, et al.Administration of live, but not inactivated, Faecalibacterium prausnitzii has a preventive effect on dextran sodium sulfate-induced colitis in mice[J].Molecular Medicine Reports, 2019, 20(1):25-32.
[10] DRABIŃSKA N, JAROCKA-CYRTA E.Crosstalk between resveratrol and gut barrier:A review[J].International Journal of Molecular Sciences, 2022, 23(23):15279.
[11] 段继娇, 谢宇潇, 朱俊红, 等.Occludin基因在猪肠道屏障中的研究进展[J].饲料研究, 2023, 46(18):140-144.
DUAN J J, XIE Y X, ZHU J H, et al.Research progress of Occludin gene in pig intestinal barrier[J].Feed Research, 2023, 46(18):140-144.
[12] 易俊, 刘小伟.炎症性肠病的肠道屏障功能研究进展[J].中华炎性肠病杂志, 2019, 3(1):41-44.
YI J, LIU X W.Research progress of intestinal barrier function in inflammatory bowel disease[J].Chinese Journal of Inflammatory Bowel Diseases, 2019, 3(1):41-44.
[13] RODA G, SARTINI A, ZAMBON E, et al.Intestinal epithelial cells in inflammatory bowel diseases[J].World Journal of Gastroenterology, 2010, 16(34):4264-4271.
[14] SALIM S Y, SÖDERHOLM J D.Importance of disrupted intestinal barrier in inflammatory bowel diseases[J].Inflammatory Bowel Diseases, 2011, 17(1):362-381.
[15] CHEN Y Y, CUI W W, LI X, et al.Interaction between commensal bacteria, immune response and the intestinal barrier in inflammatory bowel disease[J].Frontiers in Immunology, 2021, 12:761981.
[16] PRAME KUMAR K, OOI J D, GOLDBERG R.The interplay between the microbiota, diet and T regulatory cells in the preservation of the gut barrier in inflammatory bowel disease[J].Frontiers in Microbiology, 2023, 14:1291724.
[17] QIU P, ISHIMOTO T, FU L F, et al.The gut microbiota in inflammatory bowel disease[J].Frontiers in Cellular and Infection Microbiology, 2022, 12:733992.
[18] ZHANG M M, QIU X Y, ZHANG H, et al.Faecalibacterium prausnitzii inhibits interleukin-17 to ameliorate colorectal colitis in rats[J].PLoS One, 2014, 9(10):e109146.
[19] HUANG X L, ZHANG X, FEI X Y, et al.Faecalibacterium prausnitzii supernatant ameliorates dextran sulfate sodium induced colitis by regulating Th17 cell differentiation[J].World Journal of Gastroenterology, 2016, 22(22):5201-5210.
[20] PU Z C, CHE Y, ZHANG W W, et al.Dual roles of IL-18 in colitis through regulation of the function and quantity of goblet cells[J].International Journal of Molecular Medicine, 2019, 43(6):2291-2302
[21] FAGUNDES R R, BRAVO-RUISECO G, HU S X, et al.Faecalibacterium prausnitzii promotes intestinal epithelial IL-18 production through activation of the HIF1α pathway[J].Frontiers in Microbiology, 2023, 14:1298304.
[22] QIU X Y, ZHANG M M, YANG X T, et al.Faecalibacterium prausnitzii upregulates regulatory T cells and anti-inflammatory cytokines in treating TNBS-induced colitis[J].Journal of Crohn’s and Colitis, 2013, 7(11):e558-e568.
[23] TOUCH S, GODEFROY E, ROLHION N, et al.Human CD4+CD8α+ Tregs induced by Faecalibacterium prausnitzii protect against intestinal inflammation[J].JCI Insight, 2022, 7(12):e154722.
[24] ALAMEDDINE J, GODEFROY E, PAPARGYRIS L, et al.Faecalibacterium prausnitzii skews human DC to prime IL10-producing T cells through TLR2/6/JNK signaling and IL-10, IL-27, CD39, and IDO-1 induction[J].Frontiers in Immunology, 2019, 10:143.
[25] QUÉVRAIN E, MAUBERT M A, MICHON C, et al.Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn’s disease[J].Gut, 2016, 65(3):415-425.
[26] BREYNER N M, MICHON C, DE SOUSA C S, et al.Microbial anti-inflammatory molecule (MAM) from Faecalibacterium prausnitzii shows a protective effect on DNBS and DSS-induced colitis model in mice through inhibition of NF-κB pathway[J].Frontiers in Microbiology, 2017, 8:114.
[27] MIQUEL S, LECLERC M, MARTIN R, et al.Identification of metabolic signatures linked to anti-inflammatory effects of Faecalibacterium prausnitzii[J].mBio, 2015, 6(2):e00300-15.
[28] MARTÍN R, MIQUEL S, CHAIN F, et al.Faecalibacterium prausnitzii prevents physiological damages in a chronic low-grade inflammation murine model[J].BMC Microbiology, 2015, 15:67.
[29] SUZUKI T.Regulation of intestinal epithelial permeability by tight junctions[J].Cellular and Molecular Life Sciences, 2013, 70(4):631-659.
[30] WANG Y Y, MUMM J B, HERBST R, et al.IL-22 increases permeability of intestinal epithelial tight junctions by enhancing claudin-2 expression[J].Journal of Immunology (Baltimore, Md., 2017, 199(9):3316-3325.
[31] 王春晖, 杨洁, 赵宏芳, 等.普拉梭菌干预对溃疡性结肠炎小鼠免疫应答、肠道菌群、肠黏膜屏障的影响[J].海南医学院学报, 2020, 26(2):87-91.
WANG C H, YANG J, ZHAO H F, et al.Effects of Faecalibacterium prausnitzii intervention on immune response, intestinal flora and intestinal mucosal barrier of mice with ulcerative colitis[J].Journal of Hainan Medical University, 2020, 26(2):87-91.
[32] MOHEBALI N, EKAT K, KREIKEMEYER B, et al.Barrier protection and recovery effects of gut commensal bacteria on differentiated intestinal epithelial cells in vitro[J].Nutrients, 2020, 12(8):2251.
[33] XU J H, LIANG R R, ZHANG W, et al.Faecalibacterium prausnitzii-derived microbial anti-inflammatory molecule regulates intestinal integrity in diabetes mellitus mice via modulating tight junction protein expression[J].Journal of Diabetes, 2020, 12(3):224-236.
[34] MAO X Q, MA J J, JIAO C H, et al.Faecalibacterium prausnitzii attenuates DSS-induced colitis by inhibiting the colonization and pathogenicity of Candida albicans[J].Molecular Nutrition & Food Research, 2021, 65(21):e2100433.
[35] D’SOUZA G, SHITUT S, PREUSSGER D, et al.Ecology and evolution of metabolic cross-feeding interactions in bacteria[J].Natural Product Reports, 2018, 35(5):455-488.
[36] MOENS F, WECKX S, DE VUYST L.Bifidobacterial inulin-type fructan degradation capacity determines cross-feeding interactions between bifidobacteria and Faecalibacterium prausnitzii[J].International Journal of Food Microbiology, 2016, 231:76-85.
[37] FAGUNDES R R, BOURGONJE A R, SAEED A, et al.Inulin-grown Faecalibacterium prausnitzii cross-feeds fructose to the human intestinal epithelium[J].Gut Microbes, 2021, 13(1):1993582.
[38] BROWN L, WOLF J M, PRADOS-ROSALES R, et al.Through the wall:Extracellular vesicles in Gram-positive bacteria, mycobacteria and fungi[J].Nature Reviews.Microbiology, 2015, 13(10):620-630.
[39] YE L, WANG Y Z, XIAO F F, et al.F.prausnitzii-derived extracellular vesicles attenuate experimental colitis by regulating intestinal homeostasis in mice[J].Microbial Cell Factories, 2023, 22(1):235.
[40] DONOHOE D R, GARGE N, ZHANG X X, et al.The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon[J].Cell Metabolism, 2011, 13(5):517-526.
[41] ZIMMERMAN M A, SINGH N, MARTIN P M, et al.Butyrate suppresses colonic inflammation through HDAC1-dependent Fas upregulation and Fas-mediated apoptosis of T cells[J].American Journal of Physiology.Gastrointestinal and Liver Physiology, 2012, 302(12):G1405-G1415.
[42] ZHOU L X, ZHANG M M, WANG Y M, et al.Faecalibacterium prausnitzii produces butyrate to maintain Th17/treg balance and to ameliorate colorectal colitis by inhibiting histone deacetylase 1[J].Inflammatory Bowel Diseases, 2018, 24(9):1926-1940.
[43] SHIN Y, HAN S, KWON J, et al.Roles of short-chain fatty acids in inflammatory bowel disease[J].Nutrients, 2023, 15(20):4466.
[44] ZHANG M M, ZHOU L X, WANG Y M, et al.Faecalibacterium prausnitzii produces butyrate to decrease c-Myc-related metabolism and Th17 differentiation by inhibiting histone deacetylase 3[J].International Immunology, 2019, 31(8):499-514.
[45] LENOIR M, MARTÍN R, TORRES-MARAVILLA E, et al.Butyrate mediates anti-inflammatory effects of Faecalibacterium prausnitzii in intestinal epithelial cells through Dact3[J].Gut Microbes, 2020, 12(1):1826748.
[46] LI G F, LIN J, ZHANG C, et al.Microbiota metabolite butyrate constrains neutrophil functions and ameliorates mucosal inflammation in inflammatory bowel disease[J].Gut Microbes, 2021, 13(1):1968257.
[47] ISOBE J, MAEDA S, OBATA Y, et al.Commensal-bacteria-derived butyrate promotes the T-cell-independent IgA response in the colon[J].International Immunology, 2020, 32(4):243-258.
[48] FU Y F, LYU J, WANG S S.The role of intestinal microbes on intestinal barrier function and host immunity from a metabolite perspective[J].Frontiers in Immunology, 2023, 14:1277102.
[49] KHAN M T, DWIBEDI C, SUNDH D, et al.Synergy and oxygen adaptation for development of next-generation probiotics[J].Nature, 2023, 620(7973):381-385.
[50] HAN S Y, LU Y M, XIE J J, et al.Probiotic gastrointestinal transit and colonization after oral administration:A long journey[J].Frontiers in Cellular and Infection Microbiology, 2021, 11:609722.
[51] MARCIAL-COBA M S, SAABY L, KNØCHEL S, et al.Dark chocolate as a stable carrier of microencapsulated Akkermansia muciniphila and Lactobacillus casei[J].FEMS Microbiology Letters, 2019, 366(2).DOI:10.1093/femsle/fny290.
[52] SAARELA M H.Safety aspects of next generation probiotics[J].Current Opinion in Food Science, 2019, 30:8-13.
[53] BAI Z P, ZHANG N, JIN Y, et al.Comprehensive analysis of 84 Faecalibacterium prausnitzii strains uncovers their genetic diversity, functional characteristics, and potential risks[J].Frontiers in Cellular and Infection Microbiology, 2023, 12:919701.
[54] RECHARLA N, GEESALA R, SHI X Z.Gut microbial metabolite butyrate and its therapeutic role in inflammatory bowel disease:A literature review[J].Nutrients, 2023, 15(10):2275.
[55] LI J T, MU Y M, LIU Y W, et al.Effect of size and loading of retinoic acid in polyvinyl butyrate nanoparticles on amelioration of colitis[J].Polymers, 2021, 13(9):1472.
[56] BOICEAN A, BIRLUTIU V, ICHIM C, et al.Fecal microbiota transplantation in inflammatory bowel disease[J].Biomedicines, 2023, 11(4):1016.
[57] ZHANG X C, ISHIKAWA D, OHKUSA T, et al.Hot topics on fecal microbiota transplantation for the treatment of inflammatory bowel disease[J].Frontiers in Medicine, 2022, 9:1068567.
[58] CROTHERS J W, CHU N D, NGUYEN L T T, et al.Daily, oral FMT for long-term maintenance therapy in ulcerative colitis:Results of a single-center, prospective, randomized pilot study[J].BMC Gastroenterology, 2021, 21(1):281.
[59] OTT S J, WAETZIG G H, REHMAN A, et al.Efficacy of sterile fecal filtrate transfer for treating patients with Clostridium difficile infection[J].Gastroenterology, 2017, 152(4):799-811.e7.
[60] TKACH S, DOROFEYEV A, KUZENKO I, et al.Efficacy and safety of fecal microbiota transplantation via colonoscopy as add-on therapy in patients with mild-to-moderate ulcerative colitis:A randomized clinical trial[J].Frontiers in Medicine, 2023, 9:1049849.
